There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Karl Frontzek |
| Institution: | University Hospital Zurich, University of Zurich |
| Department: | Institute of Neuropathology |
| Country: | |
| Proposed Analysis: | Clinical diagnosis of Alzheimer's disease (AD) is based on a battery of neurological, serological and imaging tests which can delay accurate disease stratification and obscure effective therapy. Additionally, gold standard diagnosis is usually performed post-mortem by means of histopathology. Methylation-based diagnostics are powerful and easily accessible tools which are, however, not yet established in the realm of neurodegeneration.Our goal is to establish a blood-based, rapid diagnostic test for AD diagnosis. Previously, we have performed shallow whole-epigenome nanopore sequencing on blood from over 100 autopsy-confirmed Alzheimer's disease patients and controls suggesting a high discriminatory power for disease diagnosis. We now seek to complement our results with publicly available methylome arrays such as but not limited to the ADNI cohort. Minimal invasive diagnosis and disease stratification of AD would pave the way to effective therapeutic trials. |
| Additional Investigators |
